Business
Verisante Technology, Inc. Files Amended and Restated MD&A
Vancouver, British Columbia--(Newsfile Corp. - September 27, 2013) - Verisante Technology, I...
About this update from Verisante Technology, Inc.
[{"type":"text","content":"Verisante Technology, Inc. Files Amended and Restated MD&AVancouver, British Columbia--(Newsfile Corp. - September 27, 2013) - Verisante Technology, Inc. (TSXV: VRS) (OTCQX: VRSEF) (the \"Company\" or \"Verisante\"), a leader in cancer detection technology, announced today that, as a result of a review by the British Columbia Securities Commission, we are issuing the following press release to clarify our disclosure. Verisante has filed amended and restated management's discussion and analysis (\"MD&A\") for the period ended June 30, 2013 to include additional disclosure required by applicable regulatory requirements. The amended MD&A is available on SEDAR at www.sedar.com.The amended MD&A has been revised as follows:addition of the company's analysis of year-to-date results including a comparison of financial performance to the corresponding period in the previous year; addition of a discussion on the Company's financing during the quarter, including allocation of the proceeds of the financing, as set out under the heading \"Financing and Cash Flow\"; addition of a discussion of factors that have caused variations of results between different financial quarters, as set out under the heading \"Selected Quarterly Financial Information\"; removal of the disclosure on government grants receivable, as the Company has not directly received any grants since 2010; and addition of the disclosure of the particular terms of sale as the Company began earning revenues as set out under the heading \"Revenues\". The additional disclosure does not impact the unaudited interim condensed consolidated financial statements of the Company for the three and six months ended June 30, 2013 that have been previously filed by the Company.About Verisante Technology, Inc.Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to...